JPMorgan Downgrades Editas Medicine (EDIT) to Underweight, Following Earnings
Tweet Send to a Friend
JPMorgan analyst Cory Kasimov downgraded Editas Medicine (NASDAQ: EDIT) from ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
